Immunotherapy delays disease progression of high-grade meningiomas
The immune checkpoint inhibitor pembrolizumab showed activity against high-grade tumors of the membranes surrounding the brain and spinal column.
Video: Meet Dr. Brastianos and learn about brain metastases
Treats:
Languages:
Mass General Cancer Center: Hematology Oncology
55 Fruit St.
Boston, MA 02114
Phone: 617-724-8770
Fax: 617-724-8769
Medical Education
American Board Certifications
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Secure online access to your health information whenever you need it. Check appointments, communicate with your provider and pay bills online 24/7.
The Adolescent and Young Adult Cancer Program was created to optimize the care, outcomes, and experiences of adolescent and young adult patients.
Mass General is recognized as a top hospital on the U.S. News Best Hospitals Honor Roll for 2024-2025.
The immune checkpoint inhibitor pembrolizumab showed activity against high-grade tumors of the membranes surrounding the brain and spinal column.
A drug already in use for several cancers was found effective in a study of leptomeningeal dissemination of cancer.
In a phase 2 trial of patients with brain cancer that metastasized from a wide range of primary tumors, Mass General Cancer Center researchers found that the immune checkpoint inhibitor pembrolizumab had a durable, antitumor effect in a subset of patients.
The largest study to date of how a form of lung cancer may spread to the brain points to potential therapies for preventing or treating this deadly complication.
Mass General Cancer Center’s precision medicine approach resulted in 91 percent reduction in tumor size, with all 15 patients who received one or more cycles of therapy responding to treatment.
Immune checkpoint inhibitors caused changes to immune cells in the cerebrospinal fluid of treated patients and generated promising results in a phase II clinical trial.